Clinical Trial Update: EDIT-301 for Autologous Hematopoietic Stem Cell Transplant (HSCT) in Participants With Transfusion-Dependent Beta Thalassemia (TDT) [Phase 1, Phase 2]

View source ↗

Summary

Editas Medicine reports an update for EDIT-301, an autologous hematopoietic stem cell gene-editing therapy, currently in Phase 1/Phase 2 for transfusion-depende…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Beta-thalassemia
• Thalassemia Intermedia
• Thalassemia Major
• Transfusion-dependent Beta-thalassemia

Drugs mentioned

• EDIT-301

Snippet

Sponsor: Editas Medicine, Inc. | Conditions: Transfusion Dependent Beta Thalassemia, Hemoglobinopathies | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING